dipose tissue secretes bioactive peptides, called "adipocytokines", which act locally and distally through autocrine, paracrine and endocrine effects. [1] [2] [3] [4] An increased production of adipocytokines impacts on multiple functions such as energy balance, immunity, insulin sensitivity, angiogenesis, blood pressure, lipid metabolism and haemostasis, all of which are linked to cardiovascular diseases. Resistin has been recently identified as a novel adipose-specific cysteine-rich protein. [5] [6] [7] [8] It is a 12.5-kDa polypeptide, whose functions are not clearly established, although it has been associated with insulin resistance in rodents. It has been reported that resistin potentially links obesity to diabetes in mice with diet-induced obesity and in genetically obese mice. 9 A recent study has demonstrated that plasma resistin levels are correlated with markers of inflammation and are predictive of coronary atherosclerosis in humans. 10 Congestive heart failure (CHF) is a major and increasing health problem that causes a high mortality rate because of the increasing aging population and high prevalence of heart failure in the elderly. [11] [12] [13] However, the relationship between adipocytokines and heart failure has not been previously examined. Despite the significant reduction in mortality achieved in recent clinical trials, heart failure patients still have a poor prognosis. 14 Thus, the role of cardiac biomarkers in the evaluation and risk stratification of patients with heart failure continues to increase in importance. Therefore, the purpose of the present study was to examine whether: (1) serum levels of resistin, 1 of adipocytokines, were related to the severity of heart failure; and (2) serum resistin was useful to predict adverse clinical outcomes in patients with heart failure.
Methods

Study Population
Between January 2001 and April 2004, we prospectively enrolled 126 consecutive CHF patients (76 men and 50 women, mean age 67±13 years, range 21-92 years) who had been admitted to the Yamagata University Hospital for treatment because of worsening CHF, for the diagnosis and pathophysiological investigations, or for therapeutic evaluations of CHF. Baseline characteristics of the study popula-Background Resistin is derived from fat tissue in rodents, and serum levels are elevated in animal models of obesity and insulin resistance. Recent studies have reported that resistin is correlated with markers of inflammation and oxidative stress and is predictive of coronary atherosclerosis in humans. However, clinical significance of serum resistin has not been examined in heart failure. Therefore, the purpose of this study was to examine whether: (1) resistin is correlated with the severity of heart failure; and (2) resistin can predict clinical outcomes of patients with heart failure. Methods and Results Serum levels of resistin in 126 patients hospitalized for heart failure and 18 control subjects were measured. The patients were followed up with end-points of cardiac death and re-hospitalization caused by worsening of heart failure. The serum resistin level was higher in patients with heart failure than in control subjects and increased with advancing New York Heart Association functional class. The normal upper limit of the resistin level was determined as the mean +2 standard deviation value of control subjects (14.1 ng/ml). In heart failure patients, the cardiac event rate was higher in patients with a high resistin level than in those with a normal level. Among age, body mass index, serum levels of resistin, brain natriuretic peptide, loop diuretics selected by the univariate Cox regression hazard analysis, age and resistin were significant predictors of future cardiac events by multivariate Cox analysis. Table 1 . Exclusion criteria in the present study included: patients with clinical or electrocardiographic evidence suggestive of acute coronary syndrome within 3 months preceding admission, those with renal failure characterized by a serum creatinine concentration ≥1.5 mg/dl, and those with active hepatic or pulmonary disease. [15] [16] [17] [18] [19] Informed consent was obtained from all patients before participation in this study, and the study protocol was approved by the Human Investigations Committee of our institution.
Blood samples were obtained at admission for measurements of serum resistin levels. A 2-dimensional echocardiography was performed by an experienced cardiologist, who did not have knowledge of the biochemical data, within 1 week after admission. Clinical data, including age, sex and New York Heart Association (NYHA) functional class at admission were obtained from patient interviews and hospital medical records. The diagnosis of CHF was based on a history of dyspnea and symptomatic exercise intolerance with signs of pulmonary congestion or peripheral edema or documentation of left ventricular enlargement or dysfunction by chest X-ray film, echocardiography, or radionuclide ventriculography. [15] [16] [17] [18] [19] The etiologies of CHF were dilated cardiomyopathy in 48 patients, ischemic heart disease in 34 patients, valvular heart disease in 20 patients, and hypertensive heart disease in 12 patients. A diagnosis of hypertension, diabetes, and hyperlipidemia were obtained from medical records or patient history of currently or previously received medical therapy.
Physicians were kept blinded to the results of the biochemical markers, and optimal medical therapy was performed independently based on improvement of symptoms, physical examination findings, and pulmonary congestion on chest X-rays.
End-Points and Follow up
No patients were lost to follow up (mean follow up 645±644 days, range 29-1,080 days) after discharge. The end-points were: (1) cardiac death, defined as death from worsening CHF or sudden cardiac death; and (2) worsening CHF requiring readmission. [15] [16] [17] [18] [19] Sudden cardiac death was defined as death without definite premonitory symptoms or signs and was confirmed by the attending physician. A review of medical records and follow-up telephone interviews were conducted to survey cardiac events by 2 cardiologists, who were blinded to blood examination data. Cardiac events were adjudicated using medical records, electrocardiograms, chest X-ray reports, autopsy reports, death certificates and witness statements.
Measurement of Serum Resistin Levels
Blood samples obtained at admission for measurement of serum levels of resistin were drawn and centrifuged at 2,500 G for 15 min at 4°C within 30 min of collection, and the serum obtained was stored at -70°C until analysis. Serum resistin concentration was measured by using a sandwich enzyme-linked immunosorbent assay (ELISA, Phoenix Pharmaceutical, Inc, Belmont, CA, USA) as previously reported. 7 Intra-and inter-assay coefficients of variation were 3.4 and 6.3%, respectively.
Statistical Analysis
Data are presented as mean ± standard deviation (SD). The t-test or chi-square test was used for comparisons of continuous and categorical variables, respectively. The value below the lower detection limit of the assay was defined as zero. A Cox proportional hazard analysis was performed to determine the independent predictor of cardiac events for the entire population. Independent predictors selected in the univariate analysis were entered into the multivariate analysis. A cardiac event-free curve was computed according to the Kaplan -Meier method and compared by a log-rank test. A p value of less than 0.05 was considered as statistically significant. Statistical analysis was performed with a standard statistical program package (StatView, version 5.0, SPSS version 10.0 Institute Inc).
Results
Serum Resistin Levels in Study Subjects
Serum resistin levels were measured in 126 patients with heart failure and in 18 control subjects. As shown in Fig 1, serum resistin levels increased with advancing NYHA functional class. The normal upper limit of resistin levels was defined as mean +2SD value, and for 18 control subjects, it was 14.1 ng/ml. There were 32 patients with a high 
Resistin Levels and Cardiac Event Rates
There were 31 cardiac events including 10 cardiac deaths and 21 re-hospitalizations because of worsening heart failure during the follow-up period. Comparisons of clinical characteristics between patients with and without cardiac events are shown in Table 2 . Patients with cardiac events were older, and had more severe NYHA functional class, lower hemoglobin levels, lower high-density lipoproteincholesterol levels, higher creatinine levels, higher resistin levels, higher brain natriuretic peptide (BNP) levels, and a higher E/A ratio than those without cardiac events. Patients with cardiac events were given loop diuretics and spironolactone more frequently than event-free patients.
The cardiac event rate was compared between high and low resistin groups (Fig 2) . The cardiac event rate was significantly higher in patients with high resistin levels than those with low resistin levels (p<0.0036 by chi-square test). Kaplan -Meier survival analysis also demonstrated that the high resistin group showed a significantly lower event-free rate than the low resistin group did, as shown in Fig 3  ( p=0.0041 by log rank test). Next, patients were divided into 4 groups based on the resistin levels: 1 st quartile (1.7-6.6 ng/ml, n=31), 2 nd quartile (6.7-10.1 ng/ml, n=31), 3 rd quartile (10.2-14.0 ng/ml, n=31), and 4 th quartile (14.1-60.2 ng/ml, n=33). As shown in Fig 4, the highest 4 th quartile of resistin was associated with the highest risk for cardiac events (42.4%) compared to the other 3 groups.
Univariate and Multivariate Cox Regression Analyses
To determine the risk factors to predict cardiac events, we performed the univariate Cox proportional hazard regression analysis (Table 3 ). In the univariate analysis, serum resistin level was associated with cardiac death and rehospitalization (per 1SD increase, hazard ratio 1.357, 95% confidence interval 1.061-1.746, p<0.0145). Furthermore, age, body mass index, BNP, and the use of loop diuretics were significantly associated with cardiac death and rehospitalization.
Then, those variables with a p value of less than 0.05 in the univariate analysis were entered into the multivariate Cox proportional hazard regression analysis. As shown in Table 4 , resistin and age were independent predictors for cardiac events in patients with heart failure.
Discussion
We demonstrated that serum levels of resistin were increased in patients with heart failure, especially in those with severe heart failure (NYHA class III and IV). High resistin levels were associated with high cardiac event rates, and resistin was an independent predictor of future cardiac events by multivariate Cox regression hazard analysis.
Adipose tissue is not only a store for excess energy but also a highly active endocrine organ. [1] [2] [3] [4] The adipocytederived molecules, called adipocytokines, influence the function and structural integrity of various tissues. Leptin, a 167-amino acid protein, is expressed exclusively by adipose tissue. Leptin is a fundamental signal of satiety to the brain and a regulator of insulin and glucose metabolism. Adiponectin, one of the most abundant adipocytokines recently discovered, is a 244-amino acid protein produced by the apM1 gene, and is highly expressed in human adipose tissue. Adiponectin has anti-atherogenic and anti-inflammatory properties. Resistin is a novel adipose-specific cysteine-rich secretory protein. [5] [6] [7] [8] [9] Resistin is derived almost exclusively from fat tissue in rodents, and adipose expression and serum levels are elevated in animal models of obesity and insulin resistance. High serum levels of resistin impair glucose tolerance and induce insulin resistance in rats. 20 In contrast, mice deficient in resistin are protected from obesity-associated insulin resistance. 21 However, serum resistin was unexpectedly not correlated with body mass index and glucose levels in the present study. In addition, serum resistin levels were not different between patients with and without diabetes mellitus. Possible reasons for this include: (1) the body mass index was relatively low (23.5±3.8 kg/m 2 ) in the present study population compared to Western countries; (2) patients who were obese and who had diabetes mellitus were not common sufferers of heart failure compared to coronary heart disease; and (3) the incidence of ischemic cardiomyopathy caused by advanced coronary atherosclerosis was only 27% in the present study (Table 1) .
Serum resistin levels increased with advancing NYHA functional class and high serum resistin was associated with high cardiac event rates including cardiac death and progressive heart failure requiring re-hospitalization. Cardiac event rates increased from 1 st to 4 th quartile of resistin, and the highest 4 th quartile was associated with the highest risk compared to the other 3 groups. The univariate Cox regression analysis showed that age, body mass index, resistin, BNP and loop diuretics were significant predictors of future cardiac events in patients with heart failure. Among them, age and resistin were significant variables to predict future cardiac events by the multivariate analysis in the present study, although a number of studies have previously demonstrated that BNP is a useful tool to monitor disease outcome in patients with heart failure. 22, 23 An experimental study showed that resistin impairs cardiac recovery following ischemia through stimulation of cardiac tumor necrosis factor (TNF)-secretion. 24 Because a number of studies have demonstrated that increased levels of inflammatory cytokines including TNF-play a pathological role in heart failure, it is possible that high serum levels of resistin might cause TNF-secretion and be related to adverse clinical outcomes in the present study. We did not measure levels of TNF-and other inflammatory cytokines in this study population, and so further study is needed to support this hypothesis in humans.
Conclusion
These data suggest that resistin is useful for risk stratification of patients with heart failure and might represent a novel link between metabolic signals and heart failure.
